Competing interests
MJM: Received honoraria for consulting and scientific support from Jazz Pharmaceuticals; AA-K: Received honoraria from Celgene-BMS/Novartis/Astex/ALX Oncology/Aprea/Medimmune-AstraZeneca/H3B-Hemavant: research support. Novartis: scientific steering committee membership; AMZ participated in advisory boards, consulted, participated in clinical trial committees, and/or received honoraria from AbbVie, Akesobio, Agios, Amgen, Astellas, BioCryst, Beigene, Boehringer-Ingelheim, Celgene/BMS, Chiesi/Cornerstone biopharma, Daiichi Sankyo, Dr Reddy, Epizyme, Faron, Fibrogen, GSK, Glycomimetics, Genentech, Gilead, Geron, Janssen, Jasper, Karyopharm, Kyowa Kirin, Keros, Kura, Novartis, Notable, Orum, Otsuka, Pfizer, Regeneron, Rigel, Seattle Genetics, Shattuck labs, Schrodinger, Syros, Syndax, Servier, Takeda, Treadwell, Taiho, Vincerx, and Zentalis; DV: participated in advisory boards, consulted, participated in clinical trial committees, and/or received honoraria from AbbVie, Agios, Amgen, Asofarma, Astellas, Celgene/BMS, Grifols, Janssen, Jazz, MSD, Novartis, Pfizer, Sanofy, Servier, Sobi, Syros and Takeda.
Ethics approval and consent to participate
The study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Clinical Research Ethics Committee of Vall d’Hebron University Hospital (PR(AG)497/2018). All patients provided written informed consent. Additional approvals were obtained from the local ethics committees of participating centers when required.
